population includes erythroid, myeloid, and multipotent progenitor cell^.'^^'^ The YB5.B8 antibody also binds to the leukemic blasts from a portion of patients with acute myelogenous leukemia. " We generated a novel MoAb specific for the human c-kit receptor. This antibody, designated SR-1, blocks binding of human SCF to the c-kit receptor and neutralizes the biologic effects of SCF. Studies with SR-1 indicate that the c-kit receptor is found on a subset of marrow cells, and is broadly distributed on erythroid, myeloid, and lymphoid cell lines. Distinct epitopes on the c-kit receptor are recognized by the SR-1 and the YB5.B8 antibodies. The SR-1 antibody may be useful for functional characterization of the ligand binding domain of the c-kit receptor, and to identify and isolate hematopoietic cells that express c-kit.
MATERIALS AND METHODS

Cell lines.
The OCIMl and OCIM2 cell 1ines"were maintained in Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT). The HEL, K562, HL-60, EM-3, and KG-1 cell lines were maintained in RPMI 1640 (MA. Bioproducts, Walkersville, MD) supplemented with 10% FCS as previously described." The RM10," CEMF U528," and Daudi" cell lines were also cultured in RPMI with 10% FCS. The JK-1 cell line*' was grown in RPMI with 20% FCS. The MC/9 murine mast cell line was maintained as described.'
Immunization andfusion. An 8-week-old female Balb/C mouse received three intraperitoneal injections of lo6 OCIMl cells at 1-week intervals. Four days after the third injection, the mouse was killed by rapid cervical dislocation and the spleen was removed. Splenic cells were fused with the NSil murine myeloma cell line using 50% polyethylene glycol as described.*' Hybridomas were maintained in RPMI supplemented with pyruvate, 15% FCS, and hypoxanthine-aminopterin-thymidine medium in 96-well microtiter plates for 8 days.
A competitive binding assay was used to screen the hybridomas for anti-SCF receptor antibody production. Purified recombinant human SCF expressed in Escherichia coli was obtained from Amgen (Thousand Oaks, CA)." The SCF was iodinated by the chloramine-T method.' The specific radioactivity of the "'I-SCF was determined by radioimmunoassay performed by Dr Joan Egrie of Amgen, and was generally 2,000 to 2,500 Ci/mmol. Self-displacement analysis of SCF binding to OCIMl Hybridoma screening. OCIMl cells (3 x lo4 per tube) were added. After 1 hour in a shaking incubator at 37"C, cell-associated "'I-SCF was separated from free "'1-SCF by sedimentation through phthalate oi l : ' and 12SI-SCF in the cell pellets was quantitated in a gamma counter. Hybridoma supernatants found to inhibit binding of 1251-SCF to OCIMl cells in the initial screen were retested, and persistently positive wells were subcloned at limiting dilution on BalbiC spleen cell feeder layers, and were maintained in RF'MI 1640 supplemented with 15% FCS and hypoxanthine-thymidine. Hybridoma cells were injected into pristane-primed BalbiC mice for enhanced antibody production.
Cell lines were screened for the c-kit receptor by their ability to bind '251-SCF. The cells (2.5 x 10' per tube) were added to a mixture of '"I-SCF (0.3 nmoliL) with or without 100-fold excess unlabeled SCF in binding buffer. After 4 hours of incubation at 1 5 T , cell-bound "'I-SCF was measured as described above. Specific binding was calculated as cpm bound in the presence of '"I-SCF minus cpm bound in the presence of '"I-SCF plus excess unlabeled SCF.
The ability of the SR-1 antibody to block binding of '"I-SCF to a number of different types of cells was examined. COS-1 cells were transfected with the V19.8 vector containing sequences encoding the external and transmembrane domains of human c-kit or with the vector alone, as described.' Three days later, membrane samples were prepared3 and incubated with 0.3 nmol/L '"I-SCF with or without a 1:1,000 dilution of SR-1 ascites in binding buffer. After 1 hour of incubation at 23"C, the membranes were sedimented through phthalate oil and membrane-associated '"I-SCF was quantitated. The ability of SR-1 to block 1251-rat SCF to the murine MCi9 cell line was also assessed.
Bone marrow was aspirated from the posterior iliac crest of healthy adult volunteers. These studies were approved by the Human Subjects Committee at the University of Washington. Mononuclear cells were isolated by Ficollhypaque density centrifugation, and were depleted of macrophages by overnight adherence to plastic tissue culture flasks. The cells (10' per plate) were cultured in IMDM medium containing 1.4% methylcellulose (Dow Chemicals, Midland, MI), 30% heatinactivated FCS, 1% BSA, and penicillin/streptomy~in.~~ Partially purified human recombinant Epo (6,000 Uimg)" was used at a final concentration of 1 UlmL, and recombinant human SCF was used at a final concentration of 50 ngimL. For myeloid colony assays, recombinant GM-CSF (provided by Dr Kenneth Kaushansky, University of Washington) was used at a concentration of 2 ngimL. SR-1 ascites (generally at a final dilution of 1:1,000) or control IgG2a ascites (anti-Thy 1.1)*' were added to the methylcellulose cultures on day 0. In two experiments, SR-1 ascites was added on day 0, 2, 4, 6, or 8. Colony-forming units-erythroid (CFU-E) (colonies containing less than 50 to 60 cells) were counted on day 7, burst-forming units-erythroid (BFU-E) were counted in the same plates on day 14. CFU-granulocytemacrophage (CFU-GM) were counted on day 13 or 14.
Femoral marrow from C57 Black mice was cultured at a concentration of 1.75 x 10' cellsiml in IMDM containing 1.4% methylcellulose, 25% FCS, 1% BSA, and Epo (1 UlmL). Medium conditioned by the murine T-cell line LBRM-33, stimulated with phytohemagglutinin (PHA-LBkM), was used as a positive conBinding experiments.
Hematopoietic colony assays.
trol?" Purified recombinant rat SCF, produced in E coli , was used in some plates at a final concentration of 50 ngimL. After 8 days of incubation at 37"C, hemoglobinized erythroid colonies were counted.
To obtain CFU-GM and BFU-E progeny, nonadherent marrow mononuclear cells were cultured in methylcellulose with GM-CSF plus SCF (myeloid colonies) or Epo plus SCF (erythroid colonies) as described above. After 13 days of incubation at 37T, individual CFU-GM or BFU-E colonies were visualized under the inverted microscope and plucked." Well-hemoglobinized BFU-E colonies and pale macroscopic BFU-E colonies9 were plucked separately. For autoradiographic analysis of '251-SCF binding, peripheral blood mononuclear cells were cultured as described above except that purified recombinant human IL-3 (2 UlmL, Genetics Institute, Cambridge, MA) and Epo (1.5 UlmL) were used as the growth factors. Hemoglobinized erythroid colonies were plucked on day 13, incubated with 1 nmoliL lZSI-SCF as described above, and processed for autoradiogr a p h~.~' T lymphocytes were isolated from normal human peripheral blood mononuclear cells by the E-rosette technique using neuraminidase-treated sheep erythrocytes.
Flow cytometric analysis of SR-1 binding to normal human bone marrow cells and cell lines was performed as described." Briefly, nonadherent human bone marrow mononuclear cells or cell lines were incubated with SR-1 ascites (1:1,000 to 1:2,000 dilution) in phosphate-buffered saline (PBS) (pH 7. To determine whether exposure to SR-1 would downmodulate surface expression of the c-kit receptor, OCIMl cells were labeled with SR-1 in the presence of no inhibitors of internalization, cytochalasin B (10 FgimL), sodium azide 0.1%, or cytochalasin B plus sodium azide. Antibody labeling was performed for 30 minutes at 4"C, for 1 hour at 37"C, or for 6 hours at 37°C. The OCIMl cells were washed, incubated with FITC-conjugated goat antimouse IgG, and analyzed in an Ortho cytofluorograph as described above.
For dual-label experiments, marrow mononuclear cells were simultaneously incubated with SR-1 ascites (1:1,000 dilution) and with antibody 12. Crossblocking experiments were performed with the YB5.B8 antibody (kindly provided by Dr Leonie Ashman, University of Adelaide, Adelaide, South Australia) and the SR-1 antibody. OCIMl cells were incubated with PE-conjugated SR-1 (final concentration, 5 kg/mL) with or without YB5.BS ascites (final dilutions ranging from 1:20 to 1:1,000) for 30 minutes at 4°C. In isolation of normal hematopoietic cells.
Flow cytomefry.
use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From parallel, OCIMl cells were incubated with YB5.B8 ascites (1:1,000 final dilution) with or without SR-1 ascites (final dilutions ranging from 1:lOO to 1:1O,OOO), followed by an isotype-specific second antibody, PE-conjugated goat antibody to mouse IgGl (Caltag, San Francisco, CA) as previously described." The cells were analyzed in an Ortho cytofluorograph.
RESULTS
Antibody screening. OCIMl cells display approximately 100,000 to 200,000 high-affinity c-kit receptors per cell (H. Atkins et al, unpublished data), and were used to immunize a Balb/C mouse. Supernatants from 288 hybridoma wells were screened, and one was found to inhibit binding of IZ5I-SCF to OCIMl cells. The hybridomas in this well were subcloned, and a single positive clone was obtained. This clone was designated SR-1 (anti-SCF receptor-1). The antibody was identified as an IgG2a using a Monoclonal Typing Kit (ICN, Costa Mesa, CA). SR-1 ascites blocked binding of 1251-SCF to OCIMl cells in a dose-dependent manner (Table 1) .
To determine whether SR-1 binds to the c-kit receptor, COS cells were transfected with human c-kit and examined for SR-1 binding by indirect immunofluorescence. COS cells transfected with V19.8 alone showed no specific binding of SR-1, while approximately 5% to 10% of the COS cells transfected with the V19.8 c-kit displayed bright fluorescence with SR-1 (two experiments, data not shown). These results indicate that SR-1 binds directly to the c-kit receptor.
SR-1 was tested for its ability to block binding of SCF to COS cells expressing human c-kit (Fig 1) . Incubation with SR-1 ablated binding of IZSI-SCF to COS cells transfected with V19.8 c-kit as effectively as a 200-fold excess of unlabeled SCF. However, SR-1 did not inhibit binding of '251-rat SCF to the murine MC/9 cell line (data not shown).
A number of human hematopoietic cell lines were screened for c-kit receptor display by indirect immunofluorescence using SR-1 or by binding experiments with IzI-hSCF ( Table  2) . The results show that c-kit expression is ubiquitous; most of the human hematopoietic cell lines studied displayed the c-kit receptor. In most cases, c-kit expression was higher on erythroid than on the myeloid or lymphoid cell lines ( Table  2) use only.
For Labeling of OCIMl cells with SR-1 at 4°C and at 37°C whethcr in the presence or in the absence of inhibitors of internalization, gave identical fluorescent profiles (data not shown). These results indicate that SR-1 binding does not downmodulate surface display of the c-kit receptor.
Display of the c-kit receptor on normal human hematopoietic celh. Both CFU-GM and BFU-E progeny displayed '"I-SCF binding (Table 2) . Pale, macroscopic BFU-E : .. colonies (consisting mainly of proerythroblasts and basophilic erythroblasts) bound more than 25-fold more "'1-SCF than did well-hemoglobinized BFU-E colonies, which contained a higher proportion of late erythroblasts. Autoradiographic analysis showed binding of "'I-SCF to cultured BFU-E progeny (Fig 3) . The procrythroblasts were much more denscly labelcd than the polychromatophilic and orthochromatic erythroblasts.
Analysis of SR-1 binding by indirect immunofluorescence showed that approximately 2% to 5% of human marrow cells were positive (Fig 4A) . When the marrow cells were gated on the basis of light scattering characteristics, 13% to 17% of the cells in the "blast window" were SR-1 positive in two experiments (Fig 4) . use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 64% of the CD34-positive cells were found to display the c-kit receptor (Fig 6 ) . In two additional experiments, 59% and 69% of CD34-positive cells displayed the c-kit receptor (data not shown).
Effect of SR-1 on erythroid and myeloid colony growth. The addition of SR-1 ascites blocked the growth of the human BFU-E in vitro ( Table 3 ). The presence of SCF resulted in pale, macroscopic BFU-E colonies, as has been reported." These macroscopic BFU-E contained approximately 8,000 to 10,000 erythroid cells per BFU-E (cell count performed on 10 BFU-E). The addition of SR-1 ascites ablated these large BFU-E colonies. CFU-E growth, quantitated in the same plates, was not affected by the addition of SR-1 (Table 3) . A control antibody, anti-Thy 1.1, did not alter colony growth, and addition of SR-1 in the absence of growth factors did not stimulate colony growth (data not shown). Of note, SR-1 decreased BFU-E growth in the presence and in the absence of exogenous SCF. As was observed for BFU-E, the addition of SCF resulted in a modest increase in the numbers of CFU-GM colonies (Table 4) , and a dramatic increase in colony size. SR-1 also blocked SCF-stimulated CFU-GM growth (Table 4) . Col- ony assays with murine marrow cells showed that the addition of SR-1 did not block murine BFU-E growth, providing further confirmation that this antibody is specific for the human c-kit receptor ( Table 5) .
When the SR-1 antibody was added on various days after plating human marrow cells, an effect on both the number and size of BFU-E was noted (Fig 7) . Blocking the c-kit receptor on day 6 or 8 of culture had little effect on total BFU-E number, but decreased the fraction of macroscopic BFU-E (Fig 7) . These data show that the presence of SCF during the early stages of BFU-E growth has a profound effect on BFU-E size.
The YB5.B8 antibody recognizes the human c-kit receptor, and inhibits binding of SCF." We performed crossblocking experiments to determine whether SR-1 and YB5.B8 recognized closely related or distinct epitopes on the c-kit receptor. YB5.B8 ascites, at final dilutions ranging from 1:20 to 1:1,000, did not block binding of PE-conjugated SR-1 to OCIMl cells (data not shown). Conversely, SR-1 ascites, at final dilutions ranging from 1:lOO to 1:10,000, did not alter binding of YB5.B8 to OCIMl cells as detected by an isotype-specific second 
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Nonadherent human marrow mononuclear cells were cultured in methylcellulose with Epo (1 U/mL) 2 hSCF (50 ng/mL). SR-1 ascites (final concentration, 1:l.OOO) was added on day 0. CFU-E were counted on day 7, BFU-E were counted on day 14. The data represent the number of colonies per lo5 cells plated (average of duplicate plates) from one of three similar experiments. Three additional experiments, in which only BFU-E was quantitated, gave similar results.
antibody (Fig 8) . The PE-conjugated goat antibody to mouse IgGl did not cross-react with the SR-1 antibody, which is isotype IgG2a (Fig 8A) . These results indicate that these two neutralizing anti-c-kit MoAbs identify distinct epitopes.
DISCUSSION
MoAb SR-1 recognizes the receptor for SCF, the c-kit product, on normal human hematopoietic cells. A subset of marrow cells display the c-kit receptor, and SR-1-positive cells have the morphologic appearance of blasts. A prior evaluation using Northern blots failed to show c-kit transcripts in normal human marrow cells"; this is likely due to the relative insensitivity of Northern blot analysis in comparison to binding studies with '"1-SCF or analysis using the SR-1 or YB5.B8 antibodies." The data presented here and studies with the YB5.B8 antibody'' show that approximately 50% to 75% of CD34-positive marrow cells coexpress the c-kit protein. Experiments in which CD34-positive marrow cells were cultured at a density of one cell per well have shown that SCF acts directly on primitive progenitor cells capable of generating multiple BFU-E and CFU-GM,.'h indicating that these primitive progenitor cells must display a functional c-kit receptor. If the density of c-kit expression in these primitive multipotent cells is sufficiently high, the SR-1 antibody may be useful for isolation of cells for bone marrow transplantation.
SCF acts synergistically with lineage-specific growth factors to stimulate the growth of BFU-E and CFU-GM as well as more primitive progenitors from human marrow Our data extend these observations. SCF acts at the BFU-E stage but is not required for cell growth at the CFU-E stage; neutralizing the biologic effect of SCF with SR-1 depleted BFU-E colonies but had no effect on CFU-E growth. CFU-E continue to exhibit the c-kit receptor as direct immune adherence with SR-1 enriches CFU-E from normal marrow cells?' Ashman et al used immune rosetting with the YB5.B8 antibody to show that CFU-E express c-kit receptors." Additionally, our autoradiography data show that more mature erythroid cells (proerythroblasts) continue to bind SCF. Therefore, the lack of effect of SR-1 on CFU-E growth is not due to absence of SCF receptors.
Colony assays show that SR-1 neutralizes the biologic cffccts of SCF by completely blocking its binding to the c-kit receptor. Our data show that SR-1 profoundly inhibits BFU-E growth, and modestly inhibits CFU-GM growth. These results confirm and add to a prior report that the binding of the YB5.B8 anti-c-kit receptor antibody partially inhibits myeloid colony g r o~t h . '~ Antireceptor antibodies, whether binding to the active side or elsewhere, have been reported to mimic ligand binding.3x No evidence for this phenomenon was found with SR-1 binding to the c-kit protein.
The mechanism by which SR-1 decreases BFU-E colony growth in the absence of exogenous SCF will require further study. The FCS used for cell culture contains SCF (K. Zsebo, unpublished data), and this may enhance BFU-E growth in the presence of Epo. However, colony assays in serum-free media without added SCF continue to show the inhibitory effect of SR-1 on BFU-E gr~wth.'~ Other possibilities include SCF production by auxiliary cells present in the heterogenous population of marrow cells. Alternatively, SR-1 binding could downregulate receptors for other growth factors, or could alter intracellular signaling mechanisms. These and other potential mechanisms remain to be investigated.
Despite the fact that murine SCF is approximately equipotent on murine and human cells,* several types of evidence suggest that the active sites of murine and human c-kit receptor are antigenically distinct. SR-1 ablated binding of '"I-SCF to COS cells transfected with human c-kit and to human cell lines, but did not block binding of Iz5I-rat SCF to the murine MC/9 cell line. SR-1 did not neutralize the biologic effects of SCF in murine colony assays. The species specificity of SR-1 suggests that this MoAb may prove useful for investigation of hematopoiesis or tumor cell growth in xenograft mouse models.
SR-1 also recognizes the SCF receptor on human hematopoietic and lymphoid cell lines. With few exceptions, all of the cell lines studied display the c-kit receptor, indicating that this growth factor receptor is broadly distributed within the hematopoietic hierarchy. Certain erythroleukemia cell lines were particularly rich in SCF receptors, in accord with the prominent effect of SCF during erythropoiesis. Congenital abnormalities in either SCF production (mice with mutations at the S1 locus) or in c-kit structure (mice with mutations at the W locus) result in macrocytic anemia and reduced numbers of CFU-spleen (CFU-S) in the marrow, but normal numbers of white blood cells and platelet^,".^" although a reduction in neutrophil numbers has been reported in Sl/Sld mice. 41 MoAbs offer several advantages over the use of labeled SCF for the study of the c-kit receptor and can provide complementary information. Cells that express the c-kit receptor can be isolated from normal marrow by direct immune adherence using SR-137 or by means of fluorescenceactivated cell sorting" to determine their proliferative potential and functional characteristics. The SR-1 antibody can be used to efficiently screen both normal and neoplastic tissues for the c-kit receptor and to dissect the mechanism of SCF action. Experiments using both neutralizing and non-neutralizing antireceptor MoAbs will also be useful for structure-function analysis and to determine the SCF binding domain of the receptor. In this regard, our data show that the SR-1 and YB5.B8 MoAbs recognize distinct epitopes of the c-kit receptor. Mapping of the precise sequences recognized by these two neutralizing MoAbs should provide information about the c-kit receptor ligand binding domain.
